Payment overview · 2025
General Payments
$404.37
19 reported records · 12 companies
Healthcare provider profile · identity verified
Douglas W Edgren, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHEYENNE, WY · NPI 1033145164
Verified facts
What the public records show
CMS Open Payments records show Douglas W Edgren, MD received $404.37 in general payments during 2025 across 19 reported records.
PFIZER INC. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.82 | 18.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.47 | 16.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.62 | 13.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.20 | 9.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.13 | 8.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $24.70 | 6.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.57 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.93 | 5.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.59 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.52 | 4.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.32 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.50 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $404.37 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $72.82 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.82 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.62 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.95 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.13 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 186 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
186 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 670 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 517 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 125 |
| Losartan Potassium | Losartan Potassium | 418 | 125 |
| Metformin Hcl | Metformin Hcl | 360 | 93 |
| Lisinopril | Lisinopril | 353 | 114 |
| Gabapentin | Gabapentin | 293 | 72 |
| Omeprazole | Omeprazole | 258 | 74 |
| Simvastatin | Simvastatin | 247 | 75 |
| Furosemide | Furosemide | 221 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 57 |
| Eliquis | Apixaban | 186 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 44 |
| Allopurinol | Allopurinol | 155 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 77 |
| Potassium Chloride | Potassium Chloride | 139 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 129 | 45 |
| Montelukast Sodium | Montelukast Sodium | 109 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 17 |
| Sertraline Hcl | Sertraline Hcl | 107 | 26 |
| Trazodone Hcl | Trazodone Hcl | 107 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 98 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 26 |
| Metformin Hcl Er | Metformin Hcl | 91 | 30 |
| Meloxicam | Meloxicam | 88 | 32 |
| Finasteride | Finasteride | 85 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 21 |
| Alprazolam | Alprazolam | 74 | 20 |
| Clonazepam | Clonazepam | 73 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 28 |
| Famotidine | Famotidine | 70 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 19 |
| Warfarin Sodium | Warfarin Sodium | 68 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 20 |
| Prednisone | Prednisone | 63 | 31 |
| Buspirone Hcl | Buspirone Hcl | 62 | 19 |
| Lorazepam | Lorazepam | 60 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 11 |
| Tramadol Hcl | Tramadol Hcl | 57 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 12 |
| Spironolactone | Spironolactone | 55 | 15 |
| Aripiprazole | Aripiprazole | 52 | 11 |
| Pregabalin | Pregabalin | 50 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 18 |
| Jardiance | Empagliflozin | 48 | 13 |
| Carvedilol | Carvedilol | 47 | 14 |
| Ibuprofen | Ibuprofen | 47 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Baclofen | Baclofen | 42 | 11 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 13 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 12 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Glipizide | Glipizide | 24 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Haloperidol | Haloperidol | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Azithromycin | Azithromycin | 17 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $404.37 · 19 records | PFIZER INC. | AREXVY, BOTOX, CRYSVITA, Cologuard Collection Kit, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, PROLIA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, Wegovy, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error